Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus (RGLS – Research Report) and keeping the price target at ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on November 8. Graig ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

Sangamo Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance compared to its peers. However, it ranks in the middle for Return on Equity, suggesting ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

Growth investors, on the other hand ... Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH ...

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...